Results 71 to 80 of about 4,025 (198)
Canadian Journal of Infectious Diseases and Medical Microbiology, Volume 2026, Issue 1, 2026.Background Clostridioides difficile infection (CDI) significantly contributes to healthcare‐associated morbidity and mortality. Vaccination against C. difficile toxins may provide an effective preventive strategy, yet current data remain inconclusive. This meta‐analysis evaluates the efficacy, immunogenicity, and safety of the C.
Muhammad Shahzil +10 more
wiley +1 more source
Updated Management Guidelines for Clostridioides difficile in Paediatrics
Pathogens, 2020 Clostridioides difficile, formerly known as Clostridium difficile, causes infections (CDI) varying from self-limited diarrhoea to severe conditions, including toxic megacolon and bowel perforation.
Margherita Gnocchi +5 more
doaj +1 more source
Comparison of Fidaxomicin and Vancomycin for Recurrent Clostridium difficile Colitis
, 2017 Background Fidaxomicin is a narrow spectrum macrocyclic antibiotic used for the treatment of Clostridium difficileinfection (CDI). The objective of this study is to compare the recurrence and mortality rates of patients with CDI who ...
Luis A Marcos +4 more
core +1 more source
International Journal of Microbiology, Volume 2026, Issue 1, 2026.The pathogenic bacterium Clostridioides difficile is a major cause of antibiotic‐associated diarrheal disease. Treatment of the disease is challenging because antibiotics used for treatment may also perpetuate the conditions that contributed to initial susceptibility. Elucidating the mechanisms of C.
Paola Zucchi +10 more
wiley +1 more source
Scientifica, Volume 2026, Issue 1, 2026.Clostridioides difficile infection (CDI) remains a significant healthcare challenge, primarily due to its toxin‐mediated pathogenesis that results in severe gastrointestinal complications. This study investigates the inhibitory potential of bioactive compounds derived from Brassica oleracea L., specifically targeting the CDTa subunit of the binary ...
Ariful Islam +12 more
wiley +1 more source
, 2023 20.500.12530/87857Background Clostridioides difficile infection (CDI) is a major cause of diarrhea in hospitalized adult patients. This study aims to evaluate the clinical characteristics, clinical cure, recurrence and mortality in patients with CDI ...
de Gea Grela, Alejandro +7 more
core +1 more source
The Concise Guide to PHARMACOLOGY 2025/26: Transporters
British Journal of Pharmacology, Volume 182, Issue S1, Page S404-S496, December 2025.The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander +28 more
wiley +1 more source
Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin? [PDF]
, 2012 Until recently, treatment of Clostridium difficile infection (CDI) was mainly limited to oral metronidazole and vancomycin, neither of which is optimal. Up to 25% of patients with CDI experience recurrence of infection within 30 days following treatment ...
Cornely, O.A.
core +1 more source
ChemMedChem, Volume 20, Issue 22, November 18, 2025.Rifamycin analogues with variably functionalized C‐3 extensions provide new insight into the role of this region for MTb inhibitory activity. In addition to potentially optimizing target engagement, this region can also be used to modulate physicochemical properties, an important consideration for optimizing antimycobacterial activity.
Clinton G. L. Veale +4 more
wiley +1 more source
Piscidins synergize with fidaxomicin.
Culture density after overnight growth in the presence of the indicated concentrations of fidaxomicin and sub-inhibitory concentrations of (A) p1 or p1-Cu2+complex or (B) p3 or p3-Cu2+complex.
Asia Poudel (17827406) +11 more
core +1 more source